The Analgesic Enhancing Effects of Coupling M1 and PMC rTMS on Neuropathic Pain After Spinal Cord Injury: An fNIRS Study
Pain Research and Management · 2026
DOI: 10.1155/prm/4002703 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Research and Management, 2026. Verfasst von Xiangbo Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Xijing Hospital, Air Force Medical University (Fourth Military Medical University), Xi'an, China, fmmu.edu.cn. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Transcranial Magnetic Stimulation, Neuralgia, Motor Cortex. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Repetitive transcranial magnetic stimulation (rTMS) of the left primary motor cortex (M1) shows promise for treating neuropathic pain (NP) after spinal cord injury (SCI), but its efficacy remains limited. This study investigated whether combining rTMS on M1 with premotor cortex (PMC) could improve pain relief in SCI patients with NP. Materials and Methods Thirty‐nine subjects with NP post‐SCI were randomly assigned to three groups: M1 + PMC (10‐Hz rTMS on left M1 and PMC), M1 (10‐Hz rTMS on left M1), and sham. They underwent daily rTMS sessions for 4 weeks with 2 days off each week. Pain was assessed using the numerical rating scale (NRS) and the Short‐Form McGill Pain Questionnaire‐2 (SF‐MPQ2). Functional near‐infrared spectroscopy (fNIRS) measured activations in bilateral M1, PMC, and primary somatosensory cortex (S1) during a handgrip task.
Results
Pain intensity gradually declined in the M1 + PMC, M1, and sham groups over time. Both the M1 and M1 + PMC groups experienced greater reductions in NRS scores compared to the sham group ( p < 0.05), with the M1 + PMC group showing the most significant reduction ( p < 0.05). The M1 + PMC group showed pain relief from Weeks 1 to 6, along with notable inhibition of left M1 and the left PMC activation. The decrease in the oxyhemoglobin (HbO) concentration in the left PMC is significantly positively correlated with the improvement of the NRS score ( r = 0.607, p = 0.028) and SF‐MPQ2 ( r = 0.595, p = 0.032), respectively.
Conclusions
High‐frequency rTMS targeting both left M1 and the left PMC is more effective for NP after SCI than targeting left M1 alone, indicating a synergistic benefit. Trial Registration: Chinese Clinical Trials Registry: ChiCTR2000029024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, Xijing Hospital, Air Force Medical University (Fourth Military Medical University), Xi'an, China, fmmu.edu.cn.
- Department of Rehabilitation Medicine, Sun Yat-Sen Memorial Hospital (Shenshan Medical Center), Sun Yat-sen University, Shanwei, Guangdong, China, sysu.edu.cn.
ORCID-Profile: Xiangbo Wu, Xiaodong Lin, Baijie Xue, Fen Ju, Tao Han, Xinyu Liu, Chenguang Zhao, Xiaolong Sun, Hua Yuan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, X., Xu, M., Sun, W., Lin, X., Xue, B., Ju, F., Han, T., Liu, X., Zhao, C., Sun, X., & Yuan, H. (2026). The Analgesic Enhancing Effects of Coupling M1 and PMC rTMS on Neuropathic Pain After Spinal Cord Injury: An fNIRS Study. Pain Research and Management. https://doi.org/10.1155/prm/4002703
Vancouver
Wu X, Xu M, Sun W, Lin X, Xue B, Ju F, et al. The Analgesic Enhancing Effects of Coupling M1 and PMC rTMS on Neuropathic Pain After Spinal Cord Injury: An fNIRS Study. Pain Research and Management. 2026. doi:10.1155/prm/4002703
BibTeX
@article{Wu2026,
author = {Wu, Xiangbo and Xu, Mulan and Sun, Wei and Lin, Xiaodong and Xue, Baijie and Ju, Fen and Han, Tao and Liu, Xinyu and Zhao, Chenguang and Sun, Xiaolong and Yuan, Hua},
title = {The Analgesic Enhancing Effects of Coupling M1 and PMC rTMS on Neuropathic Pain After Spinal Cord Injury: An fNIRS Study},
journal = {Pain Research and Management},
year = {2026},
doi = {10.1155/prm/4002703}
}
EUVIMED